A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
- 1 January 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (2), 261-267
- https://doi.org/10.1016/0959-8049(94)00413-y
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.Journal of Clinical Oncology, 1994
- A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2aCancer Immunology, Immunotherapy, 1992
- Reassessment of patient response to monoclonal antibody 3F8.Journal of Clinical Oncology, 1992
- High-level expression of chimeric antibodies using adapted cDNA variable region cassettesJournal of Immunological Methods, 1989
- Gangliosides in normal human serumEuropean Journal of Biochemistry, 1989
- Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.Journal of Clinical Oncology, 1987
- The value of determination of homovanillic and vanillylmandelic acids in plasma for the diagnosis and follow-up of neuroblastoma in childrenEuropean Journal of Pediatrics, 1987
- Human Tumor AntigensAdvances in Immunology, 1987
- The Role of Meta-Iodo [131l]Benzylguanidine (Mibg) in the Diagnosis and Follow-Up of NeuroblastomaPediatric Hematology and Oncology, 1986
- SCINTIGRAPHIC IMAGING OF NEUROBLASTOMA WITH [131I]IODOBENZYLGUANIDINEThe Lancet, 1984